143 related articles for article (PubMed ID: 38385579)
1. Impact of comorbidities and body mass index on the outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of EBMT.
Polverelli N; Bonneville EF; de Wreede LC; Koster L; Kröger NM; Schroeder T; Peffault de Latour R; Passweg J; Sockel K; Broers AEC; Clark A; Dreger P; Blaise D; Yakoub-Agha I; Petersen SL; Finke J; Chevallier P; Helbig G; Rabitsch W; Sammassimo S; Arcaini L; Russo D; Drozd-Sokolowska J; Raj K; Robin M; Battipaglia G; Czerw T; Hernández-Boluda JC; McLornan DP
Am J Hematol; 2024 May; 99(5):993-996. PubMed ID: 38385579
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry.
Hernández-Boluda JC; Pereira A; Kröger N; Cornelissen JJ; Finke J; Beelen D; de Witte M; Wilson K; Platzbecker U; Sengeloev H; Blaise D; Einsele H; Sockel K; Krüger W; Lenhoff S; Salaroli A; Martin H; García-Gutiérrez V; Pavone V; Alvarez-Larrán A; Raya JM; Zinger N; Gras L; Hayden P; Czerw T; P McLornan D; Yakoub-Agha I
Am J Hematol; 2021 Oct; 96(10):1186-1194. PubMed ID: 34152630
[TBL] [Abstract][Full Text] [Related]
3. European wide survey on allogeneic haematopoietic cell transplantation practice for myelofibrosis on behalf of the EBMT chronic malignancies working party.
McLornan DP; Sirait T; Hernández-Boluda JC; Czerw T; Hayden P; Yakoub-Agha I
Curr Res Transl Med; 2021 Jan; 69(1):103267. PubMed ID: 33069640
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis-A Systematic Review and Meta-Analysis.
Bewersdorf JP; Sheth AH; Vetsa S; Grimshaw A; Giri S; Podoltsev NA; Gowda L; Tamari R; Tallman MS; Rampal RK; Zeidan AM; Stahl M
Transplant Cell Ther; 2021 Oct; 27(10):873.e1-873.e13. PubMed ID: 34052505
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic hematopoietic cell transplantation in patients with CALR-mutated myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT.
Hernández-Boluda JC; Eikema DJ; Koster L; Kröger N; Robin M; de Witte M; Finke J; Finazzi MC; Broers A; Raida L; Schaap N; Chiusolo P; Verbeek M; Hazenberg CLE; Halaburda K; Kulagin A; Labussière-Wallet H; Gedde-Dahl T; Rabitsch W; Raj K; Drozd-Sokolowska J; Battipaglia G; Polverelli N; Czerw T; Yakoub-Agha I; McLornan DP
Bone Marrow Transplant; 2023 Dec; 58(12):1357-1367. PubMed ID: 37679647
[TBL] [Abstract][Full Text] [Related]
6. Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT.
Nabergoj M; Mauff K; Robin M; Kröger N; Angelucci E; Poiré X; Passweg J; Radujkovic A; Platzbecker U; Robinson S; Rambaldi A; Petersen SL; Stölzel F; Stelljes M; Ciceri F; Mayer J; Ladetto M; de Wreede LC; Koster L; Hayden PJ; Czerw T; Hernández-Boluda JC; McLornan D; Chalandon Y; Yakoub-Agha I
Bone Marrow Transplant; 2021 Aug; 56(8):1944-1952. PubMed ID: 33824436
[TBL] [Abstract][Full Text] [Related]
7. Early liver complications after allogeneic haematopoietic stem cell transplantation in patients with myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of the EBMT.
Robin M; Gras L; Koster L; Gagelmann N; van Gorkom G; Ederr M; Itälä-Remes M; Zuckerman T; Beguin Y; Schaap N; Drozd-Sokolowska J; Raj K; Hayden PJ; de Wreede LC; Battipaglia G; Polverelli N; Czerw T; Hernandez Boluda JC; Kröger N; Yakoub-Agha I; McLornan DP
Br J Haematol; 2024 Feb; 204(2):715-718. PubMed ID: 38014808
[No Abstract] [Full Text] [Related]
8. Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT.
McLornan DP; Szydlo R; Robin M; van Biezen A; Koster L; Blok HJP; Van Lint MT; Finke J; Vitek A; Carlson K; Griskevicius L; Holler E; Itälä-Remes M; Schaap M; Socié G; Bay JO; Beguin Y; Bruno B; Cornelissen JJ; Gedde-Dahl T; Ljungman P; Rubio MT; Yakoub-Agha I; Klyuchnikov E; Olavarria E; Chalandon Y; Kröger N
Br J Haematol; 2018 Aug; 182(3):418-422. PubMed ID: 29808926
[TBL] [Abstract][Full Text] [Related]
9. Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes.
Chhabra S; Narra RK; Wu R; Szabo A; George G; Michaelis LC; D'Souza A; Dhakal B; Drobyski WR; Fenske TS; Jerkins JH; Pasquini MC; Rizzo RD; Saber W; Shah NN; Shaw BE; Hamadani M; Hari PN
Biol Blood Marrow Transplant; 2020 May; 26(5):893-901. PubMed ID: 31982543
[TBL] [Abstract][Full Text] [Related]
10. Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT).
Polverelli N; Mauff K; Kröger N; Robin M; Beelen D; Beauvais D; Chevallier P; Mohty M; Passweg J; Rubio MT; Maertens J; Finke J; Bornhäuser M; Vrhovac R; Helbig G; Mear JB; Castagna L; Reményi P; Angelucci E; Karakasis D; Rifòn J; Sirait T; Russo D; de Wreede L; Czerw T; Hernández-Boluda JC; Hayden P; McLornan D; Yakoub-Agha I
Am J Hematol; 2021 Jan; 96(1):69-79. PubMed ID: 33064301
[TBL] [Abstract][Full Text] [Related]
11. Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT.
Polverelli N; Hernández-Boluda JC; Czerw T; Barbui T; D'Adda M; Deeg HJ; Ditschkowski M; Harrison C; Kröger NM; Mesa R; Passamonti F; Palandri F; Pemmaraju N; Popat U; Rondelli D; Vannucchi AM; Verstovsek S; Robin M; Colecchia A; Grazioli L; Damiani E; Russo D; Brady J; Patch D; Blamek S; Damaj GL; Hayden P; McLornan DP; Yakoub-Agha I
Lancet Haematol; 2023 Jan; 10(1):e59-e70. PubMed ID: 36493799
[TBL] [Abstract][Full Text] [Related]
12. Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT.
Battipaglia G; Mauff K; Wendel L; Angelucci E; Mohty M; Arcese W; Santarone S; Rubio MT; Kroger N; Fox ML; Blaise D; Iori AP; Fanin R; Chalandon Y; Pioltelli P; Marotta G; Chiusolo P; Sever M; Solano C; Contentin N; de Wreede LC; Czerw T; Hernandez-Boluda JC; Hayden P; McLornan D; Yakoub-Agha I
Bone Marrow Transplant; 2021 Jul; 56(7):1593-1602. PubMed ID: 33526919
[TBL] [Abstract][Full Text] [Related]
13. Impact of donor-derived CD34 + infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT.
Czerw T; Iacobelli S; Malpassuti V; Koster L; Kröger N; Robin M; Maertens J; Chevallier P; Watz E; Poiré X; Snowden JA; Kuball J; Kinsella F; Blaise D; Reményi P; Mear JB; Cammenga J; Rubio MT; Maury S; Daguindau E; Finnegan D; Hayden P; Hernández-Boluda JC; McLornan D; Yakoub-Agha I
Bone Marrow Transplant; 2022 Feb; 57(2):261-270. PubMed ID: 34853433
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party.
McLornan DP; Hernandez-Boluda JC; Czerw T; Cross N; Joachim Deeg H; Ditschkowski M; Moonim MT; Polverelli N; Robin M; Aljurf M; Conneally E; Hayden P; Yakoub-Agha I
Leukemia; 2021 Sep; 35(9):2445-2459. PubMed ID: 34040148
[TBL] [Abstract][Full Text] [Related]
15. How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation.
Polverelli N; Farina M; D'Adda M; Damiani E; Grazioli L; Leoni A; Malagola M; Bernardi S; Russo D
Cells; 2022 Feb; 11(3):. PubMed ID: 35159362
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Pretransplantation Prediction Models for Nonrelapse Mortality in Patients with Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation.
Acosta-Medina AA; Baranwal A; Johnson IM; Kharfan-Dabaja MA; Murthy H; Palmer JM; Sproat L; Mangaonkar A; Shah MV; Hogan WJ; Litzow MR; Tefferi A; Alkhateeb HB
Transplant Cell Ther; 2023 Jun; 29(6):360.e1-360.e8. PubMed ID: 36773650
[TBL] [Abstract][Full Text] [Related]
17. Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model.
Hernández-Boluda JC; Pereira A; Alvarez-Larran A; Martín AA; Benzaquen A; Aguirre L; Mora E; González P; Mora J; Dorado N; Sampol A; García-Gutiérrez V; López-Godino O; Fox ML; Reguera JL; Pérez-Encinas M; Pascual MJ; Xicoy B; Parody R; González-Pinedo L; Español I; Avendaño A; Correa JG; Vallejo C; Jurado M; García-Cadenas I; Osorio S; Durán MA; Sánchez-Guijo F; Cervantes F; Piñana JL
Biol Blood Marrow Transplant; 2020 Dec; 26(12):2237-2244. PubMed ID: 32717433
[TBL] [Abstract][Full Text] [Related]
18. Impact of Obesity on Clinical Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies.
Voshtina E; Szabo A; Hamadani M; Fenske TS; D'Souza A; Chhabra S; Saber W; Drobyski WR; Hari P; Shah NN
Biol Blood Marrow Transplant; 2019 Jan; 25(1):e33-e38. PubMed ID: 30244105
[TBL] [Abstract][Full Text] [Related]
19. Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation.
Raj K; Eikema DJ; McLornan DP; Olavarria E; Blok HJ; Bregante S; Ciceri F; Passweg J; Ljungman P; Schaap N; Carlson K; Zuckerman T; de Wreede LC; Volin L; Koc Y; Diez-Martin JL; Brossart P; Wolf D; Blaise D; Bartolomeo PD; Vitek A; Robin M; Yakoub-Agha I; Chalandon Y; Kroger N
Biol Blood Marrow Transplant; 2019 Mar; 25(3):522-528. PubMed ID: 30408564
[TBL] [Abstract][Full Text] [Related]
20. Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
McLornan D; Szydlo R; Koster L; Chalandon Y; Robin M; Wolschke C; Beelen D; Socié G; Bornhäuser M; Angelucci E; Niederwieser D; Gerbitz A; Finke J; Vitek A; Itälä-Remes M; Radujkovic A; Kanz L; Potter V; Chevallier P; Stelljes M; Petersen E; Robinson S; Poiré X; Klyuchnikov E; Hernández-Boluda JC; Czerw T; Hayden P; Kröger N; Yakoub-Agha I
Biol Blood Marrow Transplant; 2019 Nov; 25(11):2167-2171. PubMed ID: 31284069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
